Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 19 studies | 42% ± 14% | |
endothelial cell | 11 studies | 52% ± 19% | |
T cell | 8 studies | 23% ± 6% | |
CD8-positive, alpha-beta T cell | 7 studies | 19% ± 3% | |
CD8-positive, alpha-beta memory T cell | 7 studies | 24% ± 6% | |
macrophage | 6 studies | 22% ± 7% | |
gamma-delta T cell | 6 studies | 27% ± 11% | |
mucosal invariant T cell | 5 studies | 36% ± 15% | |
monocyte | 4 studies | 19% ± 2% | |
retinal pigment epithelial cell | 4 studies | 40% ± 16% | |
dendritic cell | 4 studies | 22% ± 8% | |
regulatory T cell | 4 studies | 17% ± 2% | |
classical monocyte | 3 studies | 18% ± 2% | |
plasma cell | 3 studies | 29% ± 5% | |
retinal rod cell | 3 studies | 22% ± 8% | |
myeloid cell | 3 studies | 26% ± 1% | |
microglial cell | 3 studies | 30% ± 11% | |
conventional dendritic cell | 3 studies | 19% ± 4% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 31% ± 3% | |
astrocyte | 3 studies | 20% ± 4% | |
erythrocyte | 3 studies | 35% ± 14% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 24% ± 8% | |
CD4-positive, alpha-beta memory T cell | 3 studies | 18% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 7544.86 | 2638 / 2642 | 99% | 178.64 | 700 / 705 |
skin | 95% | 6072.65 | 1711 / 1809 | 99% | 516.76 | 465 / 472 |
stomach | 98% | 5176.23 | 351 / 359 | 86% | 125.95 | 246 / 286 |
bladder | 86% | 3262.33 | 18 / 21 | 83% | 149.21 | 419 / 504 |
esophagus | 62% | 7387.15 | 889 / 1445 | 98% | 370.47 | 180 / 183 |
intestine | 65% | 1791.24 | 631 / 966 | 91% | 134.91 | 479 / 527 |
lung | 67% | 1827.44 | 389 / 578 | 82% | 152.79 | 950 / 1155 |
breast | 43% | 1028.49 | 196 / 459 | 63% | 86.07 | 701 / 1118 |
eye | 0% | 0 | 0 / 0 | 100% | 782.59 | 80 / 80 |
ureter | 0% | 0 | 0 / 0 | 100% | 48.70 | 1 / 1 |
ovary | 53% | 1364.19 | 95 / 180 | 46% | 30.01 | 196 / 430 |
liver | 87% | 2618.96 | 197 / 226 | 11% | 6.42 | 43 / 406 |
uterus | 12% | 339.74 | 20 / 170 | 84% | 197.79 | 386 / 459 |
tonsil | 0% | 0 | 0 / 0 | 96% | 191.95 | 43 / 45 |
spleen | 93% | 3256.13 | 225 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 79% | 85.48 | 23 / 29 |
muscle | 78% | 3270.16 | 630 / 803 | 0% | 0 | 0 / 0 |
pancreas | 18% | 613.07 | 59 / 328 | 58% | 48.91 | 104 / 178 |
kidney | 46% | 1283.56 | 41 / 89 | 30% | 31.53 | 271 / 901 |
peripheral blood | 74% | 4489.52 | 691 / 929 | 0% | 0 | 0 / 0 |
prostate | 51% | 1732.35 | 126 / 245 | 6% | 2.93 | 28 / 502 |
heart | 46% | 1702.75 | 397 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 46% | 1582.32 | 613 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 16% | 389.76 | 40 / 258 | 29% | 23.73 | 67 / 230 |
thymus | 21% | 430.89 | 139 / 653 | 8% | 4.75 | 48 / 605 |
adipose | 29% | 1002.04 | 349 / 1204 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042149 | Biological process | cellular response to glucose starvation |
GO_0015821 | Biological process | methionine transport |
GO_0015823 | Biological process | phenylalanine transport |
GO_0032753 | Biological process | positive regulation of interleukin-4 production |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_1903577 | Biological process | cellular response to L-arginine |
GO_0070327 | Biological process | thyroid hormone transport |
GO_0060252 | Biological process | positive regulation of glial cell proliferation |
GO_0150104 | Biological process | transport across blood-brain barrier |
GO_0002720 | Biological process | positive regulation of cytokine production involved in immune response |
GO_0032328 | Biological process | alanine transport |
GO_0014850 | Biological process | response to muscle activity |
GO_0015818 | Biological process | isoleucine transport |
GO_0042908 | Biological process | xenobiotic transport |
GO_0015804 | Biological process | neutral amino acid transport |
GO_0089718 | Biological process | amino acid import across plasma membrane |
GO_0055093 | Biological process | response to hyperoxia |
GO_0097421 | Biological process | liver regeneration |
GO_0015829 | Biological process | valine transport |
GO_1905534 | Biological process | positive regulation of L-leucine import across plasma membrane |
GO_0003333 | Biological process | amino acid transmembrane transport |
GO_1904556 | Biological process | L-tryptophan transmembrane transport |
GO_0010507 | Biological process | negative regulation of autophagy |
GO_0015824 | Biological process | proline transport |
GO_0015828 | Biological process | tyrosine transport |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_1902024 | Biological process | L-histidine transport |
GO_1905460 | Biological process | negative regulation of vascular associated smooth muscle cell apoptotic process |
GO_1903801 | Biological process | L-leucine import across plasma membrane |
GO_0015827 | Biological process | tryptophan transport |
GO_0032740 | Biological process | positive regulation of interleukin-17 production |
GO_0015820 | Biological process | L-leucine transport |
GO_0016323 | Cellular component | basolateral plasma membrane |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0031528 | Cellular component | microvillus membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0009925 | Cellular component | basal plasma membrane |
GO_0098591 | Cellular component | external side of apical plasma membrane |
GO_1990184 | Cellular component | amino acid transport complex |
GO_0005829 | Cellular component | cytosol |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0015171 | Molecular function | amino acid transmembrane transporter activity |
GO_0015179 | Molecular function | L-amino acid transmembrane transporter activity |
GO_0015349 | Molecular function | thyroid hormone transmembrane transporter activity |
GO_0015196 | Molecular function | L-tryptophan transmembrane transporter activity |
GO_0015297 | Molecular function | antiporter activity |
GO_0015175 | Molecular function | neutral L-amino acid transmembrane transporter activity |
GO_0042605 | Molecular function | peptide antigen binding |
GO_0015173 | Molecular function | aromatic amino acid transmembrane transporter activity |
GO_0005515 | Molecular function | protein binding |
GO_0015190 | Molecular function | L-leucine transmembrane transporter activity |
Gene name | SLC7A5 |
Protein name | Large neutral amino acids transporter small subunit 1 (4F2 light chain) (4F2 LC) (4F2LC) (CD98 light chain) (Integral membrane protein E16) (E16) (L-type amino acid transporter 1) (hLAT1) (Solute carrier family 7 member 5) (y+ system cationic amino acid transporter) Large neutral amino acids transporter 1 Solute carrier family 7 (Cationic amino acid transporter, y+ system), member 5, isoform CRA_b (Solute carrier family 7 member 5) |
Synonyms | hCG_1789357 CD98LC LAT1 MPE16 |
Description | FUNCTION: The heterodimer with SLC3A2 functions as a sodium-independent, high-affinity transporter that mediates uptake of large neutral amino acids such as phenylalanine, tyrosine, leucine, histidine, methionine, tryptophan, valine, isoleucine and alanine . The heterodimer with SLC3A2 mediates the uptake of L-DOPA (By similarity). Functions as an amino acid exchanger . May play a role in the transport of L-DOPA across the blood-brain barrier (By similarity). May act as the major transporter of tyrosine in fibroblasts (Probable). May mediate blood-to-retina L-leucine transport across the inner blood-retinal barrier (By similarity).Can mediate the transport of thyroid hormones diiodothyronine (T2), triiodothyronine (T3) and thyroxine (T4) across the cell membrane . When associated with LAPTM4B, the heterodimer formed by SLC3A2 and SLC7A5 is recruited to lysosomes to promote leucine uptake into these organelles, and thereby mediates mTORC1 activation . Involved in the uptake of toxic methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes . Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the membrane . .; FUNCTION: (Microbial infection) In case of hepatitis C virus/HCV infection, the complex formed by SLC3A2 and SLC7A5/LAT1 plays a role in HCV propagation by facilitating viral entry into host cell and increasing L-leucine uptake-mediated mTORC1 signaling activation, thereby contributing to HCV-mediated pathogenesis. . |
Accessions | ENST00000565644.5 Q2MCL6 A0A0C4DGL4 Q01650 ENST00000261622.5 |